s6y

Scribe Therapeutics, Inc.

Ticker
SCTX
CIK
1853921
Industry
Biological Products, (No Diagnostic Substances)

Financials 2

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026

News 3

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing

Ownership 25

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 25 ownership filings

Prospectus 10

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  4. S-1MEF A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1
  5. S-1/A General form of registration statement for all companies including face-amount certificate companies
  6. S-1/A General form of registration statement for all companies including face-amount certificate companies
  7. S-1 General form of registration statement for all companies including face-amount certificate companies
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 9

  1. SCHEDULE 13G
  2. SCHEDULE 13G
  3. SCHEDULE 13D
  4. SCHEDULE 13D
  5. SCHEDULE 13D
  6. EFFECT Notice of Effectiveness
  7. CERT Certification by an exchange approving securities for listing
  8. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  9. D Exempt (Private) Offering